• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[克罗恩病患者粪便中α1-抗胰蛋白酶的排泄及清除情况]

[Fecal excretion and the clearance of alpha 1-antitrypsin in patients with Crohn's disease].

作者信息

López A, Hinojosa J, Miralles A, Primo J, Bermúdez J D

机构信息

Hospital de Sagunto, Universitat de València.

出版信息

Rev Esp Enferm Dig. 1993 Apr;83(4):235-9.

PMID:8494651
Abstract

In previous work we defined the normal values of faecal alpha-1 antitrypsin (A1ATF) and their plasmatic clearance (CLAT) in 25 healthy patients. The aim of the present study is to compare these previous results with new results obtained when we applied this test to 30 patients with Crohn's disease (CD). We also show the good performance of the mentioned tests as indicators of the intestinal inflammatory activity. We compare the values of A1ATF and CLAT of healthy patients with those of CD patients. We also compare the Crohn's Disease Activity Index (CDAI) and Simple Index between active and inactive CD patients. Our results show significant differences between A1ATF excretion and CLAT as measured in healthy and CD patients. The relationship between those parameters could be explained by the equation CLAT = 0.325 x A1ATF. Active and inactive CD patients only differ significantly with respect to their leucocytes and C reactive protein values. In our group the A1ATF excretion is larger in CD patients with colonic disease.

摘要

在之前的研究中,我们测定了25名健康受试者粪便α1-抗胰蛋白酶(A1ATF)的正常参考值及其血浆清除率(CLAT)。本研究旨在将上述结果与应用该检测方法检测30例克罗恩病(CD)患者的新结果进行比较。我们还证实了上述检测作为肠道炎症活动指标的良好性能。我们比较了健康受试者与CD患者的A1ATF和CLAT值。我们还比较了活动期与非活动期CD患者的克罗恩病活动指数(CDAI)和简易指数。我们的结果显示,健康受试者与CD患者的A1ATF排泄和CLAT存在显著差异。这些参数之间的关系可用公式CLAT = 0.325×A1ATF表示。活动期与非活动期CD患者仅在白细胞和C反应蛋白值上存在显著差异。在我们的研究队列中,结肠病变的CD患者A1ATF排泄量更高。

相似文献

1
[Fecal excretion and the clearance of alpha 1-antitrypsin in patients with Crohn's disease].[克罗恩病患者粪便中α1-抗胰蛋白酶的排泄及清除情况]
Rev Esp Enferm Dig. 1993 Apr;83(4):235-9.
2
Fecal excretion of alpha 1-antitrypsin in patients with Crohn's disease. A comparison of nephelometry and radial immunodiffusion.
Dig Dis Sci. 1994 Mar;39(3):507-12. doi: 10.1007/BF02088335.
3
Enteric protein loss as a marker of intestinal inflammatory activity in Crohn's disease: comparability of enteric clearance and stool concentration of alpha-1-antitrypsin?肠道蛋白丢失作为克罗恩病肠道炎症活动的标志物:α-1抗胰蛋白酶的肠道清除率与粪便浓度的可比性?
Z Gastroenterol. 1992 Oct;30(10):722-8.
4
[Initial personal experiences with alpha-1-antitrypsin determination in feces].
Schweiz Med Wochenschr. 1995 Sep 23;125(38):1783-7.
5
[Qualitative study of fecal alpha-1-antitrypsin in patients with inflammatory digestive disease and patients with ileostomy].[炎症性消化系统疾病患者和回肠造口术患者粪便α-1-抗胰蛋白酶的定性研究]
Gastroenterol Clin Biol. 1991;15(4):301-5.
6
Fecal excretion of alpha 2-macroglobulin: a novel marker for disease activity in patients with inflammatory bowel disease.α2-巨球蛋白的粪便排泄:炎症性肠病患者疾病活动的一种新标志物。
Z Gastroenterol. 1999 Jul;37(7):597-605.
7
Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.粪便钙卫蛋白与克罗恩病简单内镜评分(SES-CD)的相关性比 CRP、血白细胞和 CDAI 更密切。
Am J Gastroenterol. 2010 Jan;105(1):162-9. doi: 10.1038/ajg.2009.545. Epub 2009 Sep 15.
8
Individual fecal alpha 1-antitrypsin excretion reflects clinical activity in Crohn's disease but not in ulcerative colitis.
Hepatogastroenterology. 1999 Jul-Aug;46(28):2309-14.
9
Simplified determination of intestinal protein excretion based on alpha 1-antitrypsin clearance.基于α1-抗胰蛋白酶清除率的肠道蛋白质排泄简易测定法。
Z Gastroenterol. 1988 Mar;26(3):169-73.
10
[Initial clinical experiences with a simplified analytic method for fecal alpha-1-antitrypsin].
Z Gastroenterol. 1991 Dec;29(12):650-4.